Sydnexis

Sydnexis develops SYD-101 for pediatric progressive myopia, which is currently approved in the EU and UK, where it is licensed to Santen S.A. and marketed as Ryjunea.

Domain
Healthcare
Status
Current Private Investment
Stage of Initial Investment
Series A
Initial Investment Year
2017